Pulmonary hypertension affects approximately 1% of the global population, with prevalence rising to nearly 10% of adults over age 65. Left heart disease and lung disease (WHO Groups 2 and 3) account for the majority of cases in the Medicare population, yet PAH-specific therapies that are first-line for Group 1 carry Class III (harm) recommendations in these same groups, making accurate WHO group classification a patient safety requirement rather than a documentation formality. Precise recognition, hemodynamic confirmation by right heart catheterization, and coding specificity are among the highest-value clinical actions a primary care team can take.
AAVBC's Pulmonary Hypertension Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering WHO group classification, hemodynamic diagnostic thresholds, ICD-10 and HCC/RAF V28 coding specificity, MEAT documentation standards, the four-stratum risk stratification model, therapy escalation criteria, comorbidity screening, and referral timing. Grounded in current ESC/ERS 2022 pulmonary hypertension guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams classify PH by WHO group accurately, document clinical complexity completely, and coordinate specialist referral with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pulmonary hypertension — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Pulmonary hypertension affects approximately 1% of the global population, with prevalence rising to nearly 10% of adults over age 65. Left heart disease and lung disease (WHO Groups 2 and 3) account for the majority of cases in the Medicare population, yet PAH-specific therapies that are first-line for Group 1 carry Class III (harm) recommendations in these same groups, making accurate WHO group classification a patient safety requirement rather than a documentation formality. Precise recognition, hemodynamic confirmation by right heart catheterization, and coding specificity are among the highest-value clinical actions a primary care team can take.
AAVBC's Pulmonary Hypertension Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering WHO group classification, hemodynamic diagnostic thresholds, ICD-10 and HCC/RAF V28 coding specificity, MEAT documentation standards, the four-stratum risk stratification model, therapy escalation criteria, comorbidity screening, and referral timing. Grounded in current ESC/ERS 2022 pulmonary hypertension guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams classify PH by WHO group accurately, document clinical complexity completely, and coordinate specialist referral with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pulmonary hypertension — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
